Fusion Antibodies shares dive as no agreement with MAB yet

Antibody engineering services firm Fusion Antibodies saw its shares plummet on Wednesday as it gave advance notice of the termination of its collaboration agreement with MAB Discovery unless a new deal is struck. The collaboration agreement, which began in June 2016, dictated that Fusion would undertake high-throughput humanisation of antibodies developed by MAB, utilising the firm's CDRxTM platform. As Fusion and MAB have not yet been able to agree a revised collaboration which would "provide ...

Den vollständigen Artikel lesen ...